Kepler Capital Markets reiterated their buy rating on shares of AstraZeneca plc (LON:AZN) in a report issued on Monday. The brokerage currently has a GBX 5,200 ($67.16) target price on the biopharmaceutical company’s stock.
Several other research firms have also weighed in on AZN. Morgan Stanley restated an overweight rating and set a GBX 5,600 ($72.32) target price on shares of AstraZeneca plc in a report on Friday, June 23rd. UBS AG set a GBX 5,150 ($66.51) target price on AstraZeneca plc and gave the company a neutral rating in a report on Tuesday, June 27th. Shore Capital restated a hold rating on shares of AstraZeneca plc in a report on Wednesday, June 21st. Barclays PLC restated an overweight rating and set a GBX 6,000 ($77.49) target price on shares of AstraZeneca plc in a report on Monday, June 5th. Finally, J P Morgan Chase & Co restated a neutral rating on shares of AstraZeneca plc in a report on Monday, June 5th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the stock. The company has an average rating of Hold and a consensus price target of GBX 5,022.91 ($64.87).
AstraZeneca plc (LON:AZN) opened at 4862.00 on Monday. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00. The stock’s market cap is GBX 61.55 billion. The company has a 50-day moving average price of GBX 4,560.14 and a 200-day moving average price of GBX 4,882.27.
ILLEGAL ACTIVITY WARNING: “AstraZeneca plc’s (AZN) “Buy” Rating Reiterated at Kepler Capital Markets” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://stocknewstimes.com/2017/09/14/astrazeneca-plcs-azn-buy-rating-reiterated-at-kepler-capital-markets.html.
The company also recently announced a dividend, which was paid on Monday, September 11th. Stockholders of record on Thursday, August 10th were paid a GBX 68.90 ($0.89) dividend. This represents a dividend yield of 1.35%. The ex-dividend date was Thursday, August 10th.
In other news, insider Nazneen Rahman bought 39 shares of the business’s stock in a transaction dated Thursday, July 27th. The stock was bought at an average price of GBX 4,370 ($56.44) per share, for a total transaction of £1,704.30 ($2,201.08).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AstraZeneca plc and related companies with MarketBeat.com’s FREE daily email newsletter.